Fate Therapeutics, Inc. (NASDAQ:FATE) Director John Mendlein Sells 1,364 Shares


Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) director John Mendlein sold 1,364 shares of the company in a trade that took place on Friday, June 3. The stock was sold at an average price of $22.79, for a total value of $31,085.56. Following the sale, the director now directly owns 158,091 shares of the company, valued at $3,602,893.89. The sale was disclosed in a document filed with the SEC, accessible via this hyperlink.

John Mendlein also recently made the following trade(s):

  • On Thursday, March 10, John Mendlein sold 31,562 shares of Fate Therapeutics. The stock was sold at an average price of $35.02, for a total value of $1,105,301.24.

FATE stock was down $1.65 during Monday’s trading, hitting $22.00. 2,084,290 shares of the company were traded, against an average volume of 1,417,968. The company has a 50-day simple moving average of $30.43 and a 200-day simple moving average of $39.41. Fate Therapeutics, Inc. has a 12 month minimum of $20.49 and a 12 month maximum of $97.43. The company has a market capitalization of $2.13 billion, a price-earnings ratio of -9.03 and a beta of 1.71.

Fate Therapeutics (NASDAQ:FATE – Get Rating) last reported quarterly results on Wednesday, May 4. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, beating analyst consensus estimates of ($0.76) by $0.08. The company posted revenue of $18.40 million for the quarter, versus $9.01 million expected by analysts. Fate Therapeutics had a negative net margin of 368.76% and a negative return on equity of 34.89%. The company’s revenue increased by 65.2% compared to the same quarter last year. During the same period last year, the company achieved EPS of ($0.48). Equity research analysts expect Fate Therapeutics, Inc. to post earnings per share of -3.37 for the current fiscal year.

A number of hedge funds and other institutional investors have recently increased or reduced their stakes in the company. Exchange Traded Concepts LLC increased its equity stake in Fate Therapeutics by 21.1% during the 4th quarter. Exchange Traded Concepts LLC now owns 29,799 shares of the biopharmaceutical company valued at $1,744,000 after buying 5,201 additional shares in the last quarter. Victory Capital Management Inc. increased its position in Fate Therapeutics by 4.7% during the 4th quarter. Victory Capital Management Inc. now owns 955,312 shares of the biopharmaceutical company valued at $55,895,000 after buying an additional 43,132 shares last quarter. Capital Impact Advisors LLC acquired a new position in Fate Therapeutics during Q4, valued at approximately $597,000. Cubist Systematic Strategies LLC increased its stake in Fate Therapeutics by 331.1% in the third quarter. Cubist Systematic Strategies LLC now owns 81,034 shares of the biopharmaceutical company valued at $4,803,000 after purchasing an additional 62,238 shares last quarter. Finally, Voya Investment Management LLC increased its stake in Fate Therapeutics by 14.6% in the third quarter. Voya Investment Management LLC now owns 239,875 shares of the biopharmaceutical company worth $14,217,000 after acquiring 30,588 additional shares last quarter.

A number of research analysts have recently commented on FATE’s actions. Robert W. Baird began covering shares of Fate Therapeutics in a report on Thursday. They issued a “neutral” rating and a price target of $28.00 on the stock. StockNews.com raised shares of Fate Therapeutics to a “sell” rating in a Thursday, March 24 research note. Wedbush raised its price target on Fate Therapeutics from $74.00 to $77.00 and gave the company an “outperform” rating in a Tuesday, March 1 report. Truist Financial reduced its target price on Fate Therapeutics from $125.00 to $75.00 in a Wednesday, April 13 research report. Finally, Piper Sandler lowered her price target on Fate Therapeutics from $113.00 to $71.00 and set an “overweight” rating on the stock in a Monday, May 23 research report. One analyst rated the stock with a sell rating, three gave the company a hold rating and eight gave the company a buy rating. According to MarketBeat.com, the stock has an average buy rating and an average price target of $80.36.

Fate Therapeutics Company Profile (Get an assessment)

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK and T cell immuno-oncology programs in development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematological malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors.

Featured articles

Insider buying and selling by quarter for Fate Therapeutics (NASDAQ:FATE)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Fate Therapeutics right now?

Before you consider Fate Therapeutics, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off… and Fate Therapeutics didn’t make the list.

Although Fate Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here


Comments are closed.